NCT05407311View on ClinicalTrials.gov

64Cu-SAR-BBN for Identification of Participants With Recurrence of Prostate Cancer (SABRE)

PHASE2CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

September 19, 2022

Primary Completion Date

May 13, 2024

Study Completion Date

May 13, 2024

Conditions
Biochemical Recurrence of Malignant Neoplasm of Prostate
Interventions
DRUG

64Cu-SAR-BBN

64Cu-SAR-BBN

Trial Locations (8)

29572

Carolina Urologic Research Center, Myrtle Beach

33165

Biogenix Molecular, Miami

49503

Bamf Health, Inc, Grand Rapids

63104

St Louis University Hospital, St Louis

68130

GU Research Network, Omaha

78258

Urology San Antonio, San Antonio

90048

Tower Urology, Los Angeles

94305

Stanford University, Stanford

Sponsors
All Listed Sponsors
lead

Clarity Pharmaceuticals Ltd

INDUSTRY